title: [Monitor on influence of quality standard improvement upon Guizhi Fuling capsules efficacy].
abstract: In 2012, the preparation process and quality standard for Guizhi Fuling capsule were improved. To compare the effects and differences of capsules before (2011) and after(2012-2014) the improvement, evaluation models for intrinsic dysmenorrhea, pelvic inflammation and hysteromyoma were applied in rats. Models were induced by oxytocin, liqiud bacteria mixture and estrogen loading, respectively. The capsules (12 batchs/year, 48 bathcs in all), sampled randomly in 2011-2014, the effects were assessed using the three models. In anti-dysmenorrhea models, remarked reduction of writhing frequency, ET-1 and PGF2α content in uterus could be detected, as well as extension of writhing latency. In pelvic inflammation rats, depression of TNF-α and raise of IL-2 were induced by earh batch of capsules. In hysteromyoma model, uterine weight and smooth muscle proliferation, including E2 and P level in plasma, were lowered obviously by all batchs of capsules. Secondly, Guizhi Fuling capsules produced in 2012-2014 revealed better effectiveness than the ones manufactured in 2011. Moreover, pharmacodynamics indexes of the samples made in 2011 differed significantly between groups, which could not be observed in the ones ot 2012-2014. After tne preparation process and quality standard improvement, the effectiveness and homogeneity of Guizhi Fuling capsules were enhanced.
authors.forename: Yue
authors.initials: Y
authors.lastname: Ding
authors.forename: Ze-yui
authors.initials: ZY
authors.lastname: Cao
authors.forename: Zhi-peng
authors.initials: ZP
authors.lastname: Ke
authors.forename: Zhen-zhen
authors.initials: ZZ
authors.lastname: Su
authors.forename: Liang
authors.initials: L
authors.lastname: Cao
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.forename: Chen-feng
authors.initials: CF
authors.lastname: Zhang
authors.forename: Tuan-jie
authors.initials: TJ
authors.lastname: Wang
authors.forename: Gang
authors.initials: G
authors.lastname: Ding
authors.forename: Zhen-zhong
authors.initials: ZZ
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Xiao
mesh_terms: D000818:Animals; D002214:Capsules / Q000008:administration & dosage / Q000737:chemistry / Q000592:standards; D003863:Depression / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015237:Dinoprost / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000737:chemistry / Q000592:standards; D004412:Dysmenorrhea / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000378:metabolism; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D058996:Quality Improvement; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; C525079:guizhi-fuling; D015237:Dinoprost